UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Advances in Gene Therapy for Haemophilia.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Nathwani AC, Davidoff AM, Tuddenham EGD
  • Publication date:
    23/08/2017
  • Journal:
    Human gene therapy
  • Medium:
    Print-Electronic
  • Print ISSN:
    1043-0342
  • Language:
    eng
  • Addresses:
    University College London Cancer Institute, 192358, KD:HT Centre , The Royal Free Hospital , Pond Street , London, United Kingdom of Great Britain and Northern Ireland , NW3 2QG ; amit.nathwani@ucl.ac.uk.
Abstract
Gene therapy provides hope for a cure for patients with haemophilia by establishing continuous endogenous expression of factor VIII or factor IX following transfer of a functional gene copy to replace the haemophilic patient's own defective gene. Haemophilia may be considered a 'low hanging fruit' for gene therapy because a small increment in blood factor levels (≥2% of normal) significantly improves the bleeding tendency from severe to moderate, eliminating most spontaneous bleeds. After decades of research, the first trial to provide clear evidence of efficiency after gene transfer in patients with haemophilia B using adeno-associated viral (AAV) vectors was reported by our group in 2011. This has been followed by unprecedented activity in this area with the commencement of 7 new early Phase trials involving over 55 patients with haemophilia A or haemophilia B. These studies have, in large part, generated promising clinical data that lay a strong foundation for gene therapy to move forward rapidly to market authorisation. In this review, we discuss the data from our studies and emerging results from other gene therapy trials in both haemophilia A and B.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Research Department of Haematology
Author
Research Department of Haematology
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by